It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
DNA repair phenotype can be measured in blood and may be a potential biomarker of cancer risk. We conducted a systematic review and meta-analysis of epidemiological studies of DNA repair phenotype and cancer through March 2021. We used random-effects models to calculate pooled odds ratios (ORs) of cancer risk for those with the lowest DNA repair capacity compared with those with the highest capacity. We included 55 case–control studies that evaluated 12 different cancers using 10 different DNA repair assays. The pooled OR of cancer risk (all cancer types combined) was 2.92 (95% Confidence Interval (CI) 2.49, 3.43) for the lowest DNA repair. Lower DNA repair was associated with all studied cancer types, and pooled ORs (95% CI) ranged from 2.02 (1.43, 2.85) for skin cancer to 7.60 (3.26, 17.72) for liver cancer. All assays, except the homologous recombination repair assay, showed statistically significant associations with cancer. The effect size ranged from 1.90 (1.00, 3.60) for the etoposide-induced double-strand break assay to 5.06 (3.67, 6.99) for the γ-H2AX assay. The consistency and strength of the associations support the use of these phenotypic biomarkers; however large-scale prospective studies will be important for understanding their use related to age and screening initiation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Mailman School of Public Health of Columbia University, Department of Environmental Health Sciences, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729); Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675)
2 Mailman School of Public Health of Columbia University, Department of Epidemiology, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
3 Columbia University Irving Medical Center, Center for Radiological Research, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
4 Mailman School of Public Health of Columbia University, Department of Environmental Health Sciences, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729); Mailman School of Public Health of Columbia University, Department of Epidemiology, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)